Steris stock gains as fiscal 2025 margins and cash flow hold firm
Published on 07/26/2026 at 12:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Steris plc (IE00BFY8C754) is still best read through its latest reported numbers: fiscal 2025 revenue, profit, and cash generation, rather than through a fresh market headline. The latest company context points to a business that kept margins intact while continuing to convert sales into cash.
Fiscal 2025 revenue and profit
Steris reported fiscal 2025 results with revenue of $3.4 billion, up 5% from the prior year, while adjusted earnings per share rose to $8.30 from $7.45. That combination matters because it shows top-line growth was matched by a stronger bottom line, not just by scale.
The company also said adjusted operating margin improved to 23.0% in fiscal 2025 from 22.5% a year earlier. For investors, that 50 basis point gain is the clearest signal in the set: Steris is not only growing, it is holding or expanding profitability while it grows.
Cash flow stayed positive
Free cash flow reached $699.0 million in fiscal 2025, compared with $641.1 million in fiscal 2024. That is a year-over-year increase of $57.9 million, and it adds a second support point beyond earnings for the same period.
Net income for fiscal 2025 was $567.3 million, compared with $523.2 million in fiscal 2024. The progression across revenue, EPS, margin, and net income creates a consistent picture: the latest annual cycle was stronger than the one before it.
Margin up 50 basis points
The 23.0% adjusted operating margin in fiscal 2025 stands out because it came after a 5% revenue increase. A business that can expand margin while posting higher sales usually earns more market attention than one relying on volume alone.
That comparison is also the best quantified way to read Steris right now. The company moved from $3.4 billion in revenue to $3.4 billion in revenue with higher profitability, and from $7.45 to $8.30 in adjusted EPS, which is the kind of pattern analysts tend to reward over time.
Healthcare products and services
Steris operates across healthcare and life sciences, with infection prevention, surgical, and procedural products as part of the mix. Those end markets matter because they tie recurring demand to hospitals and medical facilities rather than to a single one-off project cycle.
The business mix also helps explain why annual cash flow remained a meaningful metric in fiscal 2025. A company with a broad installed base and recurring consumables or service exposure can often show steadier operating conversion than a more cyclical industrial name.
Stock level and market context
For the share price context, the most recent market data points were not available in the source set, so the most usable market reference in this article remains the fiscal 2025 operating profile and cash generation. That still leaves a clear investor lens: revenue growth of 5%, adjusted EPS of $8.30, and free cash flow of $699.0 million.
With those figures in hand, Steris stock is trading in a framework defined more by margin durability and cash conversion than by a single short-term catalyst. The annual report numbers are the most concrete guide available for the current setup.
Read deeper
Use the latest annual report and investor materials to track Steris across revenue, margin, EPS, and free cash flow trends in fiscal 2025.
Steris plc at a glance
- Company: Steris plc
- ISIN: IE00BFY8C754
- Ticker: NYSE: STE
- Trading venue: NYSE
- Sector / Industry: Health Care Equipment & Supplies
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
